“…Currently, reported metrics such as registry survival do not represent these benefits, most publications are case series with fewer than 100 patients, and there are no published large, high-quality randomized controlled trials comparing PFJA with TKA. 17,18,32 While appropriate selection criteria have not been validated, the presence of underlying trochlea dysplasia is associated with improved outcomes and reduced revision rates in comparison with patients who have no underlying structural cause for patellofemoral OA, 36-38 which may require further consideration.…”